Search results for " Crohn's Disease."

showing 10 items of 13 documents

The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.

2019

BACKGROUND We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. METHODS A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. RESULTS Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn's disease [CD]) were enrolled. Four hundred fifty-nine patients were naive to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One…

0301 basic medicineAdultMalemedicine.medical_specialtyAdolescentSettore MED/12 - GASTROENTEROLOGIABiosimilar; Crohn's disease; CT-P13; Inflammatory bowel disease; Inflectra; Infliximab; Remsima; Ulcerative colitis; Adolescent; Adult; Antibodies Monoclonal; Female; Follow-Up Studies; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Infliximab; Italy; Male; Prognosis; Prospective Studies; Young AdultInflectraInflammatory bowel diseaseInflammatory bowel diseaseAntibodies03 medical and health sciencesYoung Adult0302 clinical medicineGastrointestinal AgentsInternal medicineMonoclonalmedicineImmunology and AllergyHumansProspective StudiesRemsimaProspective cohort studyCrohn's diseasebusiness.industryCrohn's disease; ulcerative colitis; inflammatory bowel disease; Infliximab; Remsima; Inflectra; biosimilar; CT-P13BiosimilarSettore MED/09 - MEDICINA INTERNAGastroenterologyAntibodies Monoclonalmedicine.diseaseInflammatory Bowel DiseasesPrognosisUlcerative colitisInfliximabInfliximabCrohn's disease030104 developmental biologyUlcerative colitisItalyCohort030211 gastroenterology & hepatologyFemaleCalprotectinbusinessCT-P13Cohort studymedicine.drugFollow-Up StudiesInflammatory bowel diseases
researchProduct

Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis

2009

Objective Subclinical gut inflammation is common in spondylarthritis, but the immunologic abnormalities underlying this process are undefined. Perturbation of the interleukin-23 (IL-23)/Th17 axis has emerged as a fundamental trigger of chronic inflammation. This study was undertaken to investigate the expression and tissue distribution of IL-23/Th17–related molecules in Crohn's disease (CD) and in subclinical gut inflammation in ankylosing spondylitis (AS). Methods Quantitative gene expression analysis of Th1/Th2 and IL-23/Th17 responses was performed in intestinal biopsy samples obtained from 12 patients with CD, 15 patients with AS, and 13 controls. IL-23 tissue distribution and identific…

AdultMalePaneth Cellschronic inflammationPathologymedicine.medical_specialtyImmunologyGene ExpressionInflammationMonocytesTh2 CellsRheumatologyIntestinal mucosaIleumankylosing spondylitisPrevalencemedicineInterleukin 23HumansImmunology and Allergyinterleukin-23 (IL-23); Th 17;chronic inflammation; Crohn's disease; ankylosing spondylitisSpondylitis AnkylosingPharmacology (medical)IleitisRNA MessengerIntestinal MucosaSpondylitisinterleukin-23 (IL-23)Subclinical infectionAnkylosing spondylitisbusiness.industryInterleukin-17IleitisMiddle AgedTh1 Cellsmedicine.diseaseUp-RegulationCrohn's diseaseSTAT1 Transcription FactorTh 17ImmunologyInterleukin-23 Subunit p19FemaleInterleukin 17medicine.symptombusinessArthritis & Rheumatism
researchProduct

Correlation between fecal calprotectin and inflammation in the surgical specimen of Crohn's disease

2016

Background: An accurate assessment of the inflammatory activity is crucial to establish the most appropriate treatment in Crohn's disease (CD). The present study aimed to evaluate the utility of preoperative fecal calprotectin (FC) measurement in small bowel CD and its relationship with inflammatory activity in surgical pathology specimens. Methods: This was a prospective observational study including all the patients with small bowel CD operated on at our center between March 2011 and September 2013. Preoperative laboratory and stool tests were performed. A meticulous exploration of entire small bowel was performed during surgery, and the resected bowel (or a sample of whole intestinal wal…

AdultMalemedicine.medical_specialtyPathologymedicine.medical_treatmentInflammationGastroenterologySensitivity and SpecificitySeverity of Illness IndexSurgical pathology03 medical and health sciencesFeces0302 clinical medicineFecal calprotectinCrohn DiseaseInternal medicineIntestine SmallmedicineStrictureplastyHumansProspective StudiesSurgical pathologyProspective cohort studyAgedAged 80 and overCrohn's diseaseLeukocyte L1 Antigen Complexbusiness.industryBiomarkerMiddle Agedmedicine.diseaseSmall bowel Crohn's disease030220 oncology & carcinogenesisPreoperative PeriodBiomarker (medicine)030211 gastroenterology & hepatologySurgeryFemalemedicine.symptomCalprotectinbusinessLeukocyte L1 Antigen ComplexBiomarkers
researchProduct

Beclomethasone dipropionate in Crohn's ileitis: A randomised, double-blind trial.

2011

Abstract Background Steroids, the mainstay of Crohn's disease treatment, have been associated with systemic side effects. Aim To evaluate the efficacy and tolerability of beclomethasone dipropionate for maintaining remission induced by a short course of systemic steroids in patients with Crohn's ileitis with or without right colonic involvement. Methods Patients (n = 84) with active Crohn's disease who achieved remission during a 2-week prednisone run-in period were randomised to receive beclomethasone dipropionate for 24 weeks or continue prednisone for a further 2 weeks followed by placebo for 22 weeks. The primary outcome was relapse rate (Crohn's Disease Activity Index score > 150 and a…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaRemissionKaplan-Meier EstimateBeclomethasone dipropionate Crohn's disease RemissionPlaceboGastroenterologyDrug Administration ScheduleMedication Adherencelaw.inventionDouble blindCrohn DiseaseDouble-Blind MethodRandomized controlled triallawPrednisoneInternal medicineSecondary PreventionmedicineHumansIleitisAdverse effectGlucocorticoidsAgedCrohn's diseaseHepatologybusiness.industryRemission InductionBeclomethasoneGastroenterologyBeclomethasone dipropionate Crohn's ileitis:.Middle Agedmedicine.diseaseSurgeryBeclomethasone dipropionateCrohn's diseaseTreatment OutcomeTolerabilityPrednisoneFemaleTablets Enteric-Coatedbusinessmedicine.drug
researchProduct

Medical management of Crohn's disease

2011

The medical approach to Crohn's disease has been modified in recent years thanks to the introduction of new therapies, like biologics. Also, well-designed studies and systematic reviews have allowed better evaluation of the role of old drugs like steroids and immunosuppressors. This review aims to evaluate the recent evidence on the medical approach to Crohn's disease in the different settings of the disease.Randomized controlled trials and meta-analyses were included in the review. The research on all the studies discussed was based on the Cochrane Library, Medline and Embase, using the following medical subject headings: Crohn's disease, clinical trial, therapy, 5-aminosalicylic acid, ste…

Budesonidemedicine.medical_specialtyPathologyAnti-Inflammatory AgentsMEDLINEDiseaseCochrane LibraryManagement of Crohn's diseaselaw.inventionCrohn DiseaseRandomized controlled trialAdrenal Cortex HormoneslawmedicineHumansPharmacology (medical)BudesonideIntensive care medicineBone Marrow TransplantationPharmacologyBiological ProductsTumor Necrosis Factor-alphabusiness.industryRemission InductionGeneral Medicinemedicine.diseaseAnti-Bacterial AgentsIntestinesClinical trialAminosalicylic AcidsMethotrexateTreatment OutcomeSystematic reviewPurinesbusinessImmunosuppressive Agentsmedicine.drugExpert Opinion on Pharmacotherapy
researchProduct

Chronic Urticaria as a presenting symptom of Crohn’s disease.

2009

Clinical presentation of Crohn’s disease (CD) may be variable according to the location and the intensity of the inflammation. Some patients may have atypical symptoms which could delay the diagnosis. We report the first case of chronic urticaria related to a subclinical, complicated CD. Although the pathologic mechanism of this association was unclear in our patient, this case suggests that in patients with unexplained chronic urticaria it is opportune to investigate for a possible CD, even if there are no or few specific symptoms of intestinal inflammatory disease.

Crohn's diseasePathologymedicine.medical_specialtySettore MED/09 - Medicina Internabusiness.industryInflammationGeneral MedicineDiseasemedicine.diseaseInflammatory bowel diseaseDermatologyArticlechronic urticariaCrohn's diseaseMedicineIn patientmedicine.symptomchronic urticaria; Crohn's diseasebusinessChronic urticariaSubclinical infection
researchProduct

RHEUMATIC PATHOLOGIES IN SUBJECTS WITH INFLAMMATORY BOWEL DISEASE

2010

Inflammatory Bowel Disease (IBD) are commonly associated with rheumatic diseases of the joints. Sixty-five patients are selected during a 5-year study period. All Patients were analyzed with clinical, laboratory and radiographic exams. 38 patients had ulcerative colitis (mean age 42.1 years range:19-75) and 27 patients had Crohn's disease (CD) (mean age 37.2 years, range: 17-64 years). Arthritis occurred in 11 patients (17%): 7 with UC (18.4%) and 4 CD (14.8%). The mean age of patients with arthritis was 35 and mean disease duration of pain and limitation symptoms was 28 months. In 9 patients, arthritis appeared after the onset of bowel symptoms with mean duration of 20 months in UC and 24 …

IBD Arthritis Ulcerative Colitis Crohn's Disease.
researchProduct

Hypoxia Positively Regulates the Expression of pH-Sensing G-Protein–Coupled Receptor OGR1 (GPR68)

2016

Background & Aims: A novel family of proton-sensing G-proteinâcoupled receptors, including ovarian cancer G-proteinâcoupled receptor 1 (OGR1) (GPR68) has been identified to play a role in pH homeostasis. Hypoxia is known to change tissue pH as a result of anaerobic glucose metabolism through the stabilization of hypoxia-inducible factor-1α. We investigated how hypoxia regulates the expression of OGR1 in the intestinal mucosa and associated cells. Methods: OGR1 expression in murine tumors, human colonic tissue, and myeloid cells was determined by quantitative reverse-transcription polymerase chain reaction. The influence of hypoxia on OGR1 expression was studied in monocytes/macrophages and…

WT wild type0301 basic medicineMM6 MonoMac 6HV healthy volunteerSPARC secreted protein acidic and rich in cysteineNF-κB nuclear factor-κBInflammationBiologyIEC intestinal epithelial cell03 medical and health sciencesIntestinal mucosaTDAG8Ovarian Cancer G-Protein–Coupled ReceptormedicineOGR1 ovarian cancer G-protein–coupled receptor 1 (GPR68)IFN interferonlcsh:RC799-869ReceptorOriginal ResearchTh T-helperInflammationTNF tumor necrosis factorIBD inflammatory bowel diseaseHepatologyRT-qPCR quantitative reverse-transcription polymerase chain reactionAICAR 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranosideTDAG8 T-cell death-associated gene 8 (GPR65)Inflammatory Bowel DiseaseGRP65GastroenterologyHypoxia (medical)Molecular biologyGPR G-protein–coupled receptormRNA messenger RNAIL interleukinChIP chromatin immunoprecipitationHIF hypoxia-inducible factorUC ulcerative colitis030104 developmental biologyHypoxia-inducible factorsCancer researchCD Crohn's diseaselcsh:Diseases of the digestive system. GastroenterologyTumor necrosis factor alphaFCS fetal calf serummedicine.symptomChromatin immunoprecipitationHomeostasisCellular and Molecular Gastroenterology and Hepatology
researchProduct

Vulvar involvement in pediatric Crohn’s disease: a systematic review

2018

Purpose: The aim of the study is to report a systematic review (from 2000 to 2017) of all pediatric cases of vulvar Crohn’s disease (VCD) and to highlight the key-points for a correct diagnosis and management of this rare condition. Methods: An electronic search using the Pubmed/Medline, Scopus, EMBASE, Cochrane database and Google Scholar database was performed according to PRISMA guidelines. Results: Twenty pediatric studies and 22 cases of VCD were included for analysis. All the articles reported a single case, except two articles where two cases, respectively, are described. Clinical vulvar examination showed the following main manifestations: vulvar erythema (9/22 cases, 40.9%), vulv…

endocrine systemmedicine.medical_specialtyPediatric Crohn's diseaseVulvar edemaAdministration TopicalAdministration OralDiseasePerineumGastroenterologyVulvaPediatric Crohn’s disease030207 dermatology & venereal diseases03 medical and health sciencesPediatric Crohn’s disease0302 clinical medicineCrohn DiseaseObstetrics and gynaecologyMetronidazoleInternal medicineEdemaHumansMedicineVulvar diseaseChildbusiness.industryObstetrics and GynecologyGeneral MedicineDermatologyExtra-intestinal Crohn’s disease030220 oncology & carcinogenesisVulvar edemaFemaleVulvar DiseasesExtra-intestinal Crohn’s diseasebusinessExtra-intestinal Crohn’s disease; Pediatric Crohn’s disease; Vulvar disease; Vulvar edema; Obstetrics and Gynecology
researchProduct

Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a…

2008

medicine.medical_specialtyCrohn's diseasetherapybusiness.industryGastroenterologyCompassionate Usemedicine.diseaseCertolizumabInfliximabClinical trialPharmacotherapyRefractoryCertolizumab Crohn's disease RefractoryInternal medicinemedicineImmunology and AllergyCertolizumab pegolbusinessmedicine.drug
researchProduct